ArticleJournal of medicinal chemistry2026
New Ru(III) NAMI/NAMI-A Analogue Complexes with Selective Anticancer Activity.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
NAMI-A (ImH)[trans-RuCl4(dmso-S)(Im)], where dmso-S = sulfur-bonded dimethyl sulfoxide and Im = imidazole emerged as a promising alternative to approved Pt(II) anticancer drugs, offering high antimetastatic activity and low toxicity. However, its development was discontinued due to insufficient activity against primary tumors. In this work, we synthesized 12 new pyridine NAMI derivatives and evaluated their anticancer activity against three cancer cell lines: lung adenocarcinoma A549, melanoma MeWo and bladder cancer T24, and compared with the nonmalignant keratinocyte HaCaT cells. Among them, two complexes exhibited potent cytotoxicity and selectivity while retaining the characteristic antimetastatic activity of the NAMI scaffold. The Ru(III) complex (CHO-PyH)[trans-Ru(CHO-Py)Cl4 (dmso-S)], where CHO-Py = pyridine-3-aldehyde, displayed an IC50 of 34 μM and a selectivity index of 7.60 against A549 cells. Additionally, (NCS-PyH)[trans-RuCl4(dmso-S)(NCS-Py)], where NCS-Py = 3-(isothiocyanatomethyl)pyridine, showed an IC50 of 240 nM and a selectivity index of 5.2 against T24 cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.